Loading
A phase 1/2 trial of MHB009C for Injection in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.
A Study of MHB009C in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07326488 by Minghui Pharmaceutical (Hangzhou) Ltd, with 200 participants planned, started 2026-03-17 and due to reach its primary completion in 2028-02. Interventions recorded: MHB009C for Injection.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.